公开(公告)号：US11623920B2

公开(公告)日：2023-04-11

申请号：US17751836

申请日：2022-05-24

申请人： Nuray Chemicals Private Limited

发明人： Ramasamy Venkatragavan ,  Erugu Balaiah ,  Paramanandam Senthilkumaran ,  Guttha Jayaprasad ,  Manniyam Kailasam Selvam ,  Noti Krishnareddy ,  Sorakka Pichandi Parthipan ,  Murugan Arunkumar ,  Palaniswamy Premkumar ,  Salamuthu Kaliraj ,  Shanmugam Arumugam ,  Singavarapu Ajay Madhukar ,  Raman Silambarasan ,  Saminathan Karthick ,  Kudumudi Jayaraman Parthiban ,  Ravi Silambarasan

IPC分类号： C07D295/088 ,  A61K9/16

摘要： The present disclosure relates to a process for preparing pitolisant hydrochloride of Formula-(I) and solid-state forms thereof.

公开(公告)号：US11945788B2

公开(公告)日：2024-04-02

申请号：US18174238

申请日：2023-02-24

申请人： Nuray Chemicals Private Limited

发明人： Ramasamy Venkatragavan ,  Erugu Balaiah ,  Paramanandam Senthilkumaran ,  Guttha Jayaprasad ,  Manniyam Kailasam Selvam ,  Noti Krishnareddy ,  Sorakka Pichandi Parthipan ,  Murugan Arunkumar ,  Palaniswamy Premkumar ,  Salamuthu Kaliraj ,  Shanmugam Arumugam ,  Singavarapu Ajay Madhukar ,  Raman Silambarasan ,  Saminathan Karthick ,  Kudumudi Jayaraman Parthiban ,  Ravi Silambarasan

IPC分类号： C07D295/088 ,  C07C29/149

CPC分类号： C07D295/088 ,  C07C29/149

摘要： The present disclosure relates to a process for preparing pitolisant hydrochloride of Formula-(I) and solid-state forms thereof.

公开(公告)号：US11523993B1

公开(公告)日：2022-12-13

申请号：US17530003

申请日：2021-11-18

申请人： Nuray Chemicals Private Limited

发明人： Muthusamy Shanmugam ,  Ramasamy Venkatragavan ,  Singavarapu Ajay Madhukar ,  Erugu Balaiah ,  Palanisamy Sivakumar ,  Thirunavukkarasu Sakthikumar

IPC分类号： A61K9/48 ,  A61K9/20 ,  A61K31/167

摘要： The disclosure relates to a novel dosage form comprising hard gelatin capsule having granule composition, spray dried or evaporated composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine that would not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and that composition is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.